SEC Form 4 · accession 0001209191-18-016467

Biohaven Pharmaceutical Holding Co Ltd. · BHVN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP of Operations

Period of report

Mar 1, 2018

Accepted (ET)

Mar 5, 2018 · 4:31 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001689813

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Shares	Mar 1, 2018	M	5,000	$0.61	A	5,000	D
Common Shares^F2	Mar 1, 2018	S	2,800	$32.42	D	2,200	D
Common Shares^F3	Mar 1, 2018	S	2,200	$33.44	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F4	$0.61	Mar 1, 2018	M	5,000	D	—	Nov 25, 2024	Common Shares	5,000	37,500	D

F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.01 - $32.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.09 - $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4Immediately exercisable.